The management of cyclic vomiting syndrome in Children: Systematic Review
Abstract
Background: Cyclic Vomiting Syndrome (CVS) is a debilitating pediatric condition characterized by recurrent episodes of extreme nausea and vomiting, significantly diminishing the quality of life for affected children and their families. Its cause and optimal treatment regimen remain ambiguous, albeit heightened clinical awareness. Objective: To comprehensively evaluate and aggregate the latest information on supportive and medicinal management strategies for pediatric CVS. Methods: A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar was performed for research published from 2010 to 2025. All peer-reviewed articles that talked about behavioral, nutritional, integrative, and pharmacological therapy options were eligible. The primary things we looked at while extracting data were how well the treatment worked, how often and how long episodes happened, how often they came back, and any side effects that came with them. Results: Early administration of antiemetics, antimigraine medicines, and supportive interventions such as dietary modifications and cognitive-behavioral therapy demonstrated enhancements in long-term outcomes and a reduction in episode intensity. Nonetheless, the establishment of consistent guidelines was obstructed by discrepancies in treatment regimens and diagnostic criteria between studies. Conclusion: While additional high-quality controlled trials are necessary to provide evidence-based treatment algorithms, the current data…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.